Literature DB >> 20965490

Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.

Pedro L Moro1, Karen Broder, Yenlik Zheteyeva, Kimp Walton, Patricia Rohan, Andrea Sutherland, Alice Guh, Penina Haber, Frank Destefano, Claudia Vellozzi.   

Abstract

OBJECTIVE: The objective of the study was to characterize reports to the Vaccine Adverse Event Reporting System (VAERS) in pregnant women who received seasonal influenza vaccines to assess for potential vaccine safety concerns. STUDY
DESIGN: We searched VAERS for reports of adverse events (AEs) in pregnant women who received trivalent inactivated influenza vaccine (TIV) from July 1, 1990 through June 30, 2009, or live attenuated influenza vaccine (LAIV) from July 1, 2003, through June 30, 2009.
RESULTS: A total of 148 reports after TIV and 27 reports after LAIV were identified. Twenty TIV (13.5%) and 1 LAIV (4%) reports were classified as serious. No specific AEs were reported in 30 TIV (20.3%) and 16 LAIV (59%) reports. The most common pregnancy-specific AE was spontaneous abortion: 17 after TIV (11.5%) and 3 after LAIV (11%). The reporting rate of spontaneous abortion was 1.9 per million pregnant women vaccinated.
CONCLUSION: No unusual patterns of pregnancy complications or fetal outcomes were observed in the VAERS reports of pregnant women after the administration of TIV or LAIV. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965490     DOI: 10.1016/j.ajog.2010.08.050

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  59 in total

1.  Trends in influenza vaccine coverage in pregnant women, 2008 to 2012.

Authors:  Michelle Henninger; Bradley Crane; Allison Naleway
Journal:  Perm J       Date:  2013

Review 2.  Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance.

Authors:  Michelle H Moniz; Richard H Beigi
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

3.  The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014.

Authors: 
Journal:  Public Health Rep       Date:  2015 Jan-Feb       Impact factor: 2.792

4.  ML-Net: multi-label classification of biomedical texts with deep neural networks.

Authors:  Jingcheng Du; Qingyu Chen; Yifan Peng; Yang Xiang; Cui Tao; Zhiyong Lu
Journal:  J Am Med Inform Assoc       Date:  2019-11-01       Impact factor: 4.497

5.  Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios.

Authors:  Daniel N A Ankrah; Delese M Darko; George Sabblah; Aukje Mantel-Teeuwisse; Hubert M G Leufkens
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

Review 6.  Influenza immunization during pregnancy: Benefits for mother and infant.

Authors:  Isaac G Sakala; Yoshikazu Honda-Okubo; Johnson Fung; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

7.  Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.

Authors:  Pedro Moro; Jane Baumblatt; Paige Lewis; Janet Cragan; Naomi Tepper; Maria Cano
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

8.  Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women.

Authors:  Fubao Ma; Longhua Zhang; Renjie Jiang; Jinlin Zhang; Huaqing Wang; Xiaozhi Gao; Xiuhong Li; Yuanbao Liu
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

9.  Why Should We Advocate Maternal Immunization?

Authors:  Jim Boonyaratanakornkit; Helen Y Chu
Journal:  Pediatr Infect Dis J       Date:  2019-06       Impact factor: 2.129

10.  Maternal immunisation: ethical issues.

Authors:  Marcel Verweij; Philipp Lambach; Justin R Ortiz; Andreas Reis
Journal:  Lancet Infect Dis       Date:  2016-09-20       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.